The Clinical Effect And Experimental Study On Serum TNF-α Of Patients With Chronic Aplastic Anemia Treated By Busuishengxue Granule

Objective: To study the clinical effect and observe the difference of the expression level of serum TNF- α of patients with CAA before and after treatment, reveal the pathogenesis of CAA and and effect mechanism of Busui Shengxue Granule (BSSXG) on CAA.Method: The clinical trial was performed in open label study. Sixty patients who were taken into account were divided into experiment group and control group. Thirty patients in experiment group were treated with BSSXG, and the twenty-eight patients, two patients lost, in control group were treated with AABET (Aplastic Anemia Blood engendering Tablet ). Three months was described as one period of treatment. After two periods, clinical effect was observed and the change of hemogram, myelogram were analyze. Also, this experiment employed ELISA method to exam the change of expression level of serum TNF- α before and after treatment.RESULT: 1.The total effective rate of BSSXG and AABET were 74.29% and 48.48%. The curative effect in Yang deficiency type was superior to that in Yin deficiency type (P<0.05), and the total effective rate are 93.75% and 57.89% respectively. 2. The expression of TNF- α in the serum of CAA patients was higher than that in normal group and reduced after treatment. Moreover, the descent in experiment group was superior to that in control group, and the descent in Yin deficiency group was superior to that in Yang deficiency group. After treatment there was no significant difference in TNF- α expression level between experiment group and control group.Conclusion: l.The effect of BSSXG group was superior to that of AABET group (P<0.05). In BSSXG group, its curative effect wassuperior in Yang deficiency type to that in Yin deficiency type.This experiment testified the phenomenon of "Yin deficiency is easy to cure, but Yang deficiency is difficult to treat." 2. The expression of TNF- a in the serum of CAA patients was higher than that in normal group and cutted down after treatment. 3. BSSXG probably adjust the expression of TNF-a to improve hematopoiesis in bone marrow. 4. BSSXG is an effective drug to treat CAA, which is worthy of further study and development.